XBiotech (XBIT)
(Delayed Data from NSDQ)
$7.50 USD
+0.11 (1.49%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $7.51 +0.01 (0.13%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
XBIT 7.50 +0.11(1.49%)
Will XBIT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XBIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XBIT
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
XBIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for XBIT
XBiotech: Q2 Earnings Snapshot
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech trading resumes
XBiotech announces data from Phase 1/2 1-BETTER study